Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement awards. The company granted stock options for 60,000 shares to one new non-executive employee at $1.06 per share, and restricted stock units (RSUs) for 60,800 shares to two new non-executive employees.
The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a four-year vesting schedule. The stock options vest 25% after one year, with remaining 75% vesting monthly over 36 months, while RSUs vest 25% annually over four years.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC, ha annunciato nuovi premi per l'assunzione di dipendenti. L'azienda ha concesso opzioni su azioni per 60.000 titoli a un nuovo dipendente non esecutivo al prezzo di 1,06 $ per azione, e unit脿 azionarie vincolate (RSU) per 60.800 azioni a due nuovi dipendenti non esecutivi.
I premi, approvati dal Comitato per la Compensazione e concessi nell'ambito del Piano di Induzione Azionaria Modificato e Ristabilito dell'azienda, prevedono un piano di maturazione quadriennale. Le opzioni su azioni maturano per il 25% dopo un anno, mentre il restante 75% matura mensilmente nei successivi 36 mesi, mentre le RSU maturano per il 25% ogni anno per quattro anni.
Fate Therapeutics (NASDAQ: FATE), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en inmunoterapias celulares derivadas de iPSC, ha anunciado nuevas concesiones por inducci贸n a empleados. La empresa otorg贸 opciones sobre 60,000 acciones a un nuevo empleado no ejecutivo a $1.06 por acci贸n, y unidades de acciones restringidas (RSU) por 60,800 acciones a dos nuevos empleados no ejecutivos.
Las concesiones, aprobadas por el Comit茅 de Compensaci贸n y otorgadas bajo el Plan de Inducci贸n de Capital Modificado y Restablecido de la compa帽铆a, incluyen un programa de adquisici贸n de derechos de cuatro a帽os. Las opciones sobre acciones se adquieren en un 25% despu茅s de un a帽o, con el 75% restante que se adquiere mensualmente durante los siguientes 36 meses, mientras que las RSU se adquieren en un 25% anual durante cuatro a帽os.
Fate Therapeutics (NASDAQ: FATE)電� iPSC 鞙犽灅 靹疙彫 氅挫棴旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 鞁犼窚 歆侅洂 鞙犽弰 氤挫儊鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 60,000欤检棎 雽�頃� 欤检嫕 鞓奠厴鞚� 牍勳瀯鞗� 鞁犾瀰 歆侅洂 1氇呾棎瓴� 欤茧嫻 1.06雼煬鞐� 攵�鞐枅鞙茧┌, 60,800欤检潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 牍勳瀯鞗� 鞁犾瀰 歆侅洂 2氇呾棎瓴� 攵�鞐枅鞀惦媹雼�.
鞚� 氤挫儊鞚� 氤挫儊 鞙勳洂須岇潣 鞀轨澑鞚� 氚涭晿鞙茧┌ 須岇偓鞚� 靾橃爼 氚� 鞛爼牍勲悳 鞙犽弰 欤检嫕 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堦碃, 4雲勱皠鞚� 氩犾姢韺� 鞚检爼鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 欤检嫕 鞓奠厴鞚� 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿�, 雮橂ǜ歆� 75%電� 36臧滌洈鞐� 瓯胳硱 毵れ洈 氩犾姢韺呺悩氅�, RSU電� 4雲勳棎 瓯胳硱 毵る厔 25%鞌� 氩犾姢韺呺惄雼堧嫟.
Fate Therapeutics (NASDAQ : FATE), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les immunoth茅rapies cellulaires d茅riv茅es d'iPSC, a annonc茅 de nouvelles attributions incitatives pour les employ茅s. La soci茅t茅 a accord茅 des options d'achat d'actions pour 60 000 titres 脿 un nouvel employ茅 non cadre au prix de 1,06 $ par action, ainsi que des unit茅s d'actions restreintes (RSU) pour 60 800 actions 脿 deux nouveaux employ茅s non cadres.
Ces attributions, approuv茅es par le comit茅 de r茅mun茅ration et accord茅es dans le cadre du Plan d'Attribution d'Actions Modifi茅 et Restitu茅 de la soci茅t茅, comprennent un calendrier d'acquisition sur quatre ans. Les options d'achat d'actions s'acqui猫rent 脿 hauteur de 25 % apr猫s un an, le reste de 75 % s'acqu茅rant mensuellement sur 36 mois, tandis que les RSU s'acqui猫rent 脿 raison de 25 % par an sur quatre ans.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf iPSC-abgeleitete zellul盲re Immuntherapien spezialisiert hat, hat neue Anreizpr盲mien f眉r Mitarbeiter bekannt gegeben. Das Unternehmen gew盲hrte Aktienoptionen f眉r 60.000 Aktien an einen neuen nicht-exekutiven Mitarbeiter zu 1,06 $ pro Aktie sowie Restricted Stock Units (RSUs) f眉r 60.800 Aktien an zwei neue nicht-exekutive Mitarbeiter.
Die Pr盲mien, genehmigt vom Verg眉tungsausschuss und gew盲hrt im Rahmen des ge盲nderten und neu gefassten Inducement Equity Plans des Unternehmens, umfassen einen Vesting-Zeitraum von vier Jahren. Die Aktienoptionen vesten zu 25 % nach einem Jahr, die restlichen 75 % vesten monatlich 眉ber 36 Monate, w盲hrend die RSUs j盲hrlich zu 25 % 眉ber vier Jahre vesten.
- None.
- None.
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on August 4, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 60,000 shares of the Company鈥檚 common stock at an exercise price per share of
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company鈥檚 pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
[email protected]
FAQ
What stock options did Fate Therapeutics (FATE) grant to new employees in August 2025?
How many RSUs did Fate Therapeutics award in August 2025?
What is the vesting schedule for Fate Therapeutics' August 2025 stock options?
What is Fate Therapeutics' main business focus?
